Lyell Immunopharma, Inc. (LYEL) — Stock Score Summary

Lyell Immunopharma, Inc. (LYEL) has a MoatMap StockRank of 9/100 based on Quality (25/100), Value (38/100), and Momentum (27/100) factor scores. The current signal is STRONG SELL. Lyell Immunopharma is an early-stage cell therapy biotech with no commercial products or CDMO pricing power. It does not meet our criteria for high ROIC and predictable owner earnings.

Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company developing novel cell therapies for cancer. It focuses on overcoming key challenges in cell therapy, such as T-cell exhaustion and poor trafficking, through innovative genetic and epigenetic reprogramming technologies. Lyell is a biotech innovator dedicated to enhancing the durability, potency, and localization of T-cells to improve cancer treatments.

Key Financial Metrics

Price$12.70
Market Cap$393M
P/E (Forward)-15.54
Price/Book1.11
Return on Equity-80.8%
Return on Invested Capital-69.4%
Debt/Equity17.85
Gross Margin100.0%
Operating Margin-2213050.0%
Revenue Growth-71.4%
Free Cash Flow$-77M

Lyell Immunopharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Lyell Immunopharma, Inc.’s (LYEL) StockRank?
MoatMap’s StockRank for Lyell Immunopharma, Inc. (LYEL) is 9/100, with a Strong Sell signal. It is a composite of Quality (25), Value (38), and Momentum (27) factor ranks across MoatMap’s 19,000+ stock universe.
Does Lyell Immunopharma, Inc. have an economic moat?
Lyell Immunopharma, Inc. (LYEL) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Lyell Immunopharma, Inc. a buy, hold, or sell?
MoatMap’s current signal for Lyell Immunopharma, Inc. (LYEL) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Lyell Immunopharma, Inc. in?
Lyell Immunopharma, Inc. (LYEL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksLYEL deep dive reportAI ChampionsHow we score stocksSense-check another stock